Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay

Hye young Wang, Sungwoo Ahn, Sunghyun Kim, Sunyoung Park, Dongju Jung, Sangjung Park, Hyunju Han, Joo Hyuk Sohn, Seung Il Kim, Hyeyoung Lee

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Breast cancer is a highly prevalent disease among women worldwide. While the expression of certain proteins within breast cancer tumors is used to determine the prognosis and select therapies, additional markers need to be identified. Circulating tumor cells (CTCs) are constituent cells that have detached from a primary tumor to circulate in the bloodstream. CTCs are considered the main source of breast cancer metastases; therefore, detection of CTCs could be a promising diagnostic method for metastatic breast cancer. Methods: In this study, the CircleGen CTC RT-qDx assay was used to analyze the mRNA expression levels of six CTC-specific markers including EpCAM, CK19, HER2, Ki67, hTERT, and vimentin with a total of 692 peripheral whole blood samples from 221 breast cancer patients and 376 healthy individuals. Results: This assay showed high specificity with multiple markers; none of the healthy controls were detected positive, whereas 21.7 and 14 % of breast cancer patients were positive for EpCAM and CK19, respectively. Of the 221 breast cancer patients, 84 (38 %), 46 (20.8 %), 83 (37.6 %), and 39 (17.6 %) were positively for HER2, Ki67, hTERT, and vimentin mRNA, respectively. Of the 84 patients who were HER2 positive, nine (4 %) were also positive for EpCAM, CK19, Ki67, hTERT, and vimentin. Of the 139 breast cancer patients who were HER2 negative, 65 (29.1 %) were negative for EpCAM, CK19, Ki67, hTERT, and vimentin. Furthermore, the EpCAM-positive population decreased from 21.5 to 8.3 % after completion of anti-tumor treatment (TP4). Similarly, the CK19, HER2, hTERT, and vimentin positives also decreased from 13.9 to 9.5 %, from 37.7 to 21.4 %, from 37.2 to 33.3 %, and from 17.5 to 14.3 %, respectively, after completion of anti-tumor treatment. In contrast, the Ki67 positives increased from 20.6 to 41.7 % after completion of anti-tumor treatment. Conclusions: mRNA overexpression of six CTC-specific markers was detected by the CircleGen CTC RT-qDx assay with high specificity, and the obtained mRNA expression levels of CTC-specific markers might provide useful criteria to select appropriate anti-tumor treatment for breast cancer patients.

Original languageEnglish
Pages (from-to)878-890
Number of pages13
JournalInternational Journal of Clinical Oncology
Volume20
Issue number5
DOIs
Publication statusPublished - 2015 Oct 3

Fingerprint

Circulating Neoplastic Cells
Breast Neoplasms
Polymerase Chain Reaction
Vimentin
Messenger RNA
Neoplasms
Therapeutics
Epithelial Cell Adhesion Molecule
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hematology
  • Oncology

Cite this

Wang, Hye young ; Ahn, Sungwoo ; Kim, Sunghyun ; Park, Sunyoung ; Jung, Dongju ; Park, Sangjung ; Han, Hyunju ; Sohn, Joo Hyuk ; Kim, Seung Il ; Lee, Hyeyoung. / Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay. In: International Journal of Clinical Oncology. 2015 ; Vol. 20, No. 5. pp. 878-890.
@article{64f3167ee4824095996b3003c1951d83,
title = "Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay",
abstract = "Background: Breast cancer is a highly prevalent disease among women worldwide. While the expression of certain proteins within breast cancer tumors is used to determine the prognosis and select therapies, additional markers need to be identified. Circulating tumor cells (CTCs) are constituent cells that have detached from a primary tumor to circulate in the bloodstream. CTCs are considered the main source of breast cancer metastases; therefore, detection of CTCs could be a promising diagnostic method for metastatic breast cancer. Methods: In this study, the CircleGen CTC RT-qDx assay was used to analyze the mRNA expression levels of six CTC-specific markers including EpCAM, CK19, HER2, Ki67, hTERT, and vimentin with a total of 692 peripheral whole blood samples from 221 breast cancer patients and 376 healthy individuals. Results: This assay showed high specificity with multiple markers; none of the healthy controls were detected positive, whereas 21.7 and 14 {\%} of breast cancer patients were positive for EpCAM and CK19, respectively. Of the 221 breast cancer patients, 84 (38 {\%}), 46 (20.8 {\%}), 83 (37.6 {\%}), and 39 (17.6 {\%}) were positively for HER2, Ki67, hTERT, and vimentin mRNA, respectively. Of the 84 patients who were HER2 positive, nine (4 {\%}) were also positive for EpCAM, CK19, Ki67, hTERT, and vimentin. Of the 139 breast cancer patients who were HER2 negative, 65 (29.1 {\%}) were negative for EpCAM, CK19, Ki67, hTERT, and vimentin. Furthermore, the EpCAM-positive population decreased from 21.5 to 8.3 {\%} after completion of anti-tumor treatment (TP4). Similarly, the CK19, HER2, hTERT, and vimentin positives also decreased from 13.9 to 9.5 {\%}, from 37.7 to 21.4 {\%}, from 37.2 to 33.3 {\%}, and from 17.5 to 14.3 {\%}, respectively, after completion of anti-tumor treatment. In contrast, the Ki67 positives increased from 20.6 to 41.7 {\%} after completion of anti-tumor treatment. Conclusions: mRNA overexpression of six CTC-specific markers was detected by the CircleGen CTC RT-qDx assay with high specificity, and the obtained mRNA expression levels of CTC-specific markers might provide useful criteria to select appropriate anti-tumor treatment for breast cancer patients.",
author = "Wang, {Hye young} and Sungwoo Ahn and Sunghyun Kim and Sunyoung Park and Dongju Jung and Sangjung Park and Hyunju Han and Sohn, {Joo Hyuk} and Kim, {Seung Il} and Hyeyoung Lee",
year = "2015",
month = "10",
day = "3",
doi = "10.1007/s10147-015-0798-3",
language = "English",
volume = "20",
pages = "878--890",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "5",

}

Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay. / Wang, Hye young; Ahn, Sungwoo; Kim, Sunghyun; Park, Sunyoung; Jung, Dongju; Park, Sangjung; Han, Hyunju; Sohn, Joo Hyuk; Kim, Seung Il; Lee, Hyeyoung.

In: International Journal of Clinical Oncology, Vol. 20, No. 5, 03.10.2015, p. 878-890.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay

AU - Wang, Hye young

AU - Ahn, Sungwoo

AU - Kim, Sunghyun

AU - Park, Sunyoung

AU - Jung, Dongju

AU - Park, Sangjung

AU - Han, Hyunju

AU - Sohn, Joo Hyuk

AU - Kim, Seung Il

AU - Lee, Hyeyoung

PY - 2015/10/3

Y1 - 2015/10/3

N2 - Background: Breast cancer is a highly prevalent disease among women worldwide. While the expression of certain proteins within breast cancer tumors is used to determine the prognosis and select therapies, additional markers need to be identified. Circulating tumor cells (CTCs) are constituent cells that have detached from a primary tumor to circulate in the bloodstream. CTCs are considered the main source of breast cancer metastases; therefore, detection of CTCs could be a promising diagnostic method for metastatic breast cancer. Methods: In this study, the CircleGen CTC RT-qDx assay was used to analyze the mRNA expression levels of six CTC-specific markers including EpCAM, CK19, HER2, Ki67, hTERT, and vimentin with a total of 692 peripheral whole blood samples from 221 breast cancer patients and 376 healthy individuals. Results: This assay showed high specificity with multiple markers; none of the healthy controls were detected positive, whereas 21.7 and 14 % of breast cancer patients were positive for EpCAM and CK19, respectively. Of the 221 breast cancer patients, 84 (38 %), 46 (20.8 %), 83 (37.6 %), and 39 (17.6 %) were positively for HER2, Ki67, hTERT, and vimentin mRNA, respectively. Of the 84 patients who were HER2 positive, nine (4 %) were also positive for EpCAM, CK19, Ki67, hTERT, and vimentin. Of the 139 breast cancer patients who were HER2 negative, 65 (29.1 %) were negative for EpCAM, CK19, Ki67, hTERT, and vimentin. Furthermore, the EpCAM-positive population decreased from 21.5 to 8.3 % after completion of anti-tumor treatment (TP4). Similarly, the CK19, HER2, hTERT, and vimentin positives also decreased from 13.9 to 9.5 %, from 37.7 to 21.4 %, from 37.2 to 33.3 %, and from 17.5 to 14.3 %, respectively, after completion of anti-tumor treatment. In contrast, the Ki67 positives increased from 20.6 to 41.7 % after completion of anti-tumor treatment. Conclusions: mRNA overexpression of six CTC-specific markers was detected by the CircleGen CTC RT-qDx assay with high specificity, and the obtained mRNA expression levels of CTC-specific markers might provide useful criteria to select appropriate anti-tumor treatment for breast cancer patients.

AB - Background: Breast cancer is a highly prevalent disease among women worldwide. While the expression of certain proteins within breast cancer tumors is used to determine the prognosis and select therapies, additional markers need to be identified. Circulating tumor cells (CTCs) are constituent cells that have detached from a primary tumor to circulate in the bloodstream. CTCs are considered the main source of breast cancer metastases; therefore, detection of CTCs could be a promising diagnostic method for metastatic breast cancer. Methods: In this study, the CircleGen CTC RT-qDx assay was used to analyze the mRNA expression levels of six CTC-specific markers including EpCAM, CK19, HER2, Ki67, hTERT, and vimentin with a total of 692 peripheral whole blood samples from 221 breast cancer patients and 376 healthy individuals. Results: This assay showed high specificity with multiple markers; none of the healthy controls were detected positive, whereas 21.7 and 14 % of breast cancer patients were positive for EpCAM and CK19, respectively. Of the 221 breast cancer patients, 84 (38 %), 46 (20.8 %), 83 (37.6 %), and 39 (17.6 %) were positively for HER2, Ki67, hTERT, and vimentin mRNA, respectively. Of the 84 patients who were HER2 positive, nine (4 %) were also positive for EpCAM, CK19, Ki67, hTERT, and vimentin. Of the 139 breast cancer patients who were HER2 negative, 65 (29.1 %) were negative for EpCAM, CK19, Ki67, hTERT, and vimentin. Furthermore, the EpCAM-positive population decreased from 21.5 to 8.3 % after completion of anti-tumor treatment (TP4). Similarly, the CK19, HER2, hTERT, and vimentin positives also decreased from 13.9 to 9.5 %, from 37.7 to 21.4 %, from 37.2 to 33.3 %, and from 17.5 to 14.3 %, respectively, after completion of anti-tumor treatment. In contrast, the Ki67 positives increased from 20.6 to 41.7 % after completion of anti-tumor treatment. Conclusions: mRNA overexpression of six CTC-specific markers was detected by the CircleGen CTC RT-qDx assay with high specificity, and the obtained mRNA expression levels of CTC-specific markers might provide useful criteria to select appropriate anti-tumor treatment for breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84942980741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942980741&partnerID=8YFLogxK

U2 - 10.1007/s10147-015-0798-3

DO - 10.1007/s10147-015-0798-3

M3 - Article

VL - 20

SP - 878

EP - 890

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 5

ER -